Left ventricular dysfunction in the haemodialysis population

NDT Plus

Volumn 1, Issue 4, 2008, Pages 199-205

  Sood, Manish M ^a   Pauly, Robert P ^b   Rigatto, Claudio ^a   Komenda, Paul ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; FOSINOPRIL; PLACEBO;

CARDIAC RESYNCHRONIZATION THERAPY; DEFIBRILLATION; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 48749099983     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn074     Document Type: Review

References (71)

1. USRDS. USRDS 2006 Annual Data Report. The National Institute of Health. Am J Kidney Dis 2006; 49 (Suppl 1): S1
2. Jassal S, Trpeski L, Zhu N et al. Changes in survival among elderly patients initiating dialysis from 1990 to 1999. CMAJ 2007; 177: 1033-1038
3. Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38: 992-1000
4. Collins AJ. Impact of congestive heart failure and other cardiac diseases on patient outcomes. Kidney Int Suppl 2002; 8: S3-S7.
5. Trespalacios FC, Taylor AJ et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003; 41: 1267-1277
6. Silberberg JS, Barre PE et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290
7. Zoccali C, Benedetto FA. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774
8. Zoccali C, Benedetto FA et al. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol 2004; 15: 1029-1037
9. FoleyRN, Parfrey P et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J AmSoc Nephrol 1995; 5: 2024-2031
10. London GM, Pannier B et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767
11. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45(Suppl 3): S1-S153.
12. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
13. Levy D, Savage DD et al. Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 1987; 59: 956-960
14. Foley RN, Parfrey PS et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192
15. Foley RN, Parfrey PS et al. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54: 1720-1725
16. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 3): S112-S119
17. Harnett JD, Foley RN et al. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-890
18. Parfrey PS, Foley RN et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277-1285
19. Mallamaci F, Zoccali C, Tripepi G et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001; 59: 1559-1566
20. Joki N, Hase H et al. Combined assessment of cardiac systolic dysfunction and coronary atherosclerosis used to predict future cardiac deaths after starting hemodialysis. Am J Nephrol 2003; 23: 458-465
21. Greaves SC, Gamble GD et al. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis 1994; 24: 768-776
22. Zoccali C, Benedetto FA, Mallamaci F et al. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol 2000; 15: 1029-1037
23. Bouchard J, Madore F. Inadequate treatment of congestive heart failure in dialysis patients. Semin Dial 2007; 20: 383-386
24. Ritz E, DikowR et al. Congestive heart failure due to systolic dysfunction: The Cinderella of cardiovascular management in dialysis patients. Semin Dial 2002; 15: 135-140
25. Levin A, Thompson CR et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
26. Levin A, Lewis M et al. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354
27. Portoles J, Torralbo A et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548
28. Kuriyama S, Tomonari H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185
29. Foley RN, Parfrey PS et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
30. Besarab A, Bolton WK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
31. Mahadevan G, Davis RC et al. Left ventricular ejection fraction: Are the revised cut-off points for defining systolic dysfunction sufficiently evidence based? Heart 2008; 94: 426-428
32. Parfrey PS, Collingwood P et al. Left ventricular disorders detected by M-mode echocardiography in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1328-1331.
33. Kilickap M, Sayin T et al. Intravascular volume dependency of left ventricular mass calculation by two-dimensional guided M-mode echocardiography. Can J Cardiol 2006; 23: 219-222.
34. Hartnett JD, Collingwood P et al. The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron 1993; 65: 3
35. Martin LC, Cornejo IV et al. Influence of fluid volume variations on the calculated value of left ventricular mass measured by echocardiogram in patients submitted to hemodialysis. Ren Fail 2003; 25: 43-53
36. Stewart GA, Foster J et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999; 56: 2248-2253
37. Sugeng L, Weinnert L et al. Quantitative assessment of left ventricular size and function-side by side comparison of real-time three dimensional echocardiography and computed tomography with magnetic resonance reference. Circulation 2007; 114: 654-661
38. mcIntyre CW, Selby NM et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. CJASN 2007; 3: 19-26
39. Furgeson S, Chonchol M. Beta-blockade in chronic dialysis patients. Semin Dial 2008; 21: 43-48
40. Cice G, Di Benedetto A et al. Dilated cardiomyopathy in dialysis patients - beneficial effects of carvedilol: A double-blind, placebocontrolled trial. J Am Coll Cardiol 2001; 41: 1438-1444
41. Cice G, D'Andrea A et al. Cardvedilol increases two year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebocontrolled trail. J Am Coll Cardiol 2003; 41: 1438-1444
42. Hayashi A, Kaneshiro M, Takemitsu Y et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis 2005; 45: 866-874.
43. ShibasakiY,Nishiue T et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256-261
44. Suzuki H, Okada H et al. A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial 2003; 19: 59-66
45. Li PK, Wong TY et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139: 105-112
46. Zannad F, Lehert P et al. Prevention of cardiovascular events in endstage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324
47. Takahashi A, Takase H et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis_a randomized study. Nephrol Dial Transplant 2006; 21: 2507-2512
48. Trespalacios FC, Agodoa LY et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003; 41: 1267-1277
49. Cleland JG, Jafri S et al. TheWarfarin/Aspirin Study in Heart Failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148: 157-164
50. USRDS. Atlas of end-stage renal disease in the United States. USRDS 2006 Annual Data Report. National Institute of Diabetes and Digestive Kidney Disease 2006
51. Bleyer AJ, Tell GS et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006; 69: 2268-2273
52. ACC/AHA. Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2005; 112: E154-e235
53. Herzog CA, Li S et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005; 68: 818-825
54. Abraham WT, FW, Smith AL et al. for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853
55. Bristow MR, Saxon LA et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150
56. Saxon LA, Bristow MR et al. Predictors of sudden cardiac death and appropriate shock in the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) trial. Circulation 2006; 114: 2766-2772
57. Bloom H, Heeke B et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol 2006; 29: 142-145
58. Dasgupta A,Montalvo J et al. Increased complication rates of cardiac rhythm management devices in ESRD patients.Am J Kidney Dis 2007; 49: 656-663
59. Stack AG,Molony DA et al. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int 2003; 64: 1071-1079
60. Enia G, Mallamaci F et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1459-1464
61. Konings CJ, Kooman JP et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 2002; 22: 477-487
62. Koc M, Toprak A et al. Uncontrolled hypertension due to volume overload contributes to higher left ventricular mass index in CAPD patients. Nephrol Dial Transplant 2002; 17: 16 61-1666
63. Konings CJAM, Kooman JP et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int 2003; 63: 1556-1563
64. Asci G, Ozkahya M et al. Volume control associated with better cardiac function in long-term peritoneal dialysis patients. Perit Dial Int 2006; 26: 85-88
65. Fagugli R, Reboldi G et al. Short daily hemodialysis: Blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 2001; 38: 371-376
66. Traeger J, Galland R et al. Six years' experience with short daily hemodialysis: Do the early improvements persist in the mid and long term? Hemodialysis Int 2004; 8: 151-158
67. Pauly RP, Chan CT. Reversing the risk factor paradox: Is daily nocturnal hemodialysis the solution? Semin Dial 2007; 20: 539-543
68. Chan CT, Floras JS et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61: 2235-2239
69. Chan C et al. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant 2002; 17: 1518-1521
70. Culleton BF et al. Effect of frequent nocturnal hemodialysis versus conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA 2007; 298: 1291-1299
71. Chan CT et al. Short-termblood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003; 42: 925-931